A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer-Reference-Cited by-同舟云学术

A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer

Published:2017-08-22 Issue:1 Volume:17 Page:
ISSN:1471-2490
Container-title:BMC Urology
language:en
Short-container-title:BMC Urol

Author:

Kim Hae Su,Lee Ji Yun,Lee Su Jin,Lim Ho Yeong,Sung Hyun Hwan,Jeon Hwang Gyun,Jeong Byong Chang,Seo Seong Il,Jeon Seong Soo,Lee Hyun Moo,Choi Han-Yong,Park Se Hoon^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Urology,Reproductive Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12894-017-0253-z.pdf

Reference22 articles.

1. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–41.

2. Damber JE, Aus G. Prostate cancer. Lancet. 2008;371:1710–21.

3. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985;3:827–41.

4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy;ESMO Open;2023-04

2. Comparison of 2-Weekly and 3-Weekly Dosing of Docetaxel in Metastatic Prostate Cancer;Clinical Genitourinary Cancer;2022-08

3. A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer;BMC Cancer;2021-11-29

4. Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer;Cancer Investigation;2021-01-14

5. Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer;Anticancer Research;2020-07-29